Updates are available Correction dated 2021-10-07
Click to view Correction: https://doi.org/10.1038/s41467-021-26291-y
-
Authors
Lin, Gu-Lung https://orcid.org/0000-0002-9950-318X
Drysdale, Simon B. https://orcid.org/0000-0002-6350-6557
Snape, Matthew D.
O’Connor, Daniel https://orcid.org/0000-0002-6902-9886
Brown, Anthony https://orcid.org/0000-0001-6751-3300
MacIntyre-Cockett, George
Mellado-Gomez, Esther
de Cesare, Mariateresa https://orcid.org/0000-0002-9847-1526
Bonsall, David
Ansari, M. Azim
Öner, Deniz
Aerssens, Jeroen
Butler, Christopher
Bont, Louis
Openshaw, Peter https://orcid.org/0000-0002-7220-2555
Martinón-Torres, Federico https://orcid.org/0000-0002-9023-581X
Nair, Harish https://orcid.org/0000-0002-9432-9100
Bowden, Rory https://orcid.org/0000-0001-8596-0366
,
Campbell, Harry
Cunningham, Steve
Bogaert, Debby
Beutels, Philippe
Wildenbeest, Joanne
Clutterbuck, Elizabeth
McGinley, Joseph
Thwaites, Ryan
Wiseman, Dexter
Gómez-Carballa, Alberto
Rodriguez-Tenreiro, Carmen
Rivero-Calle, Irene
Dacosta-Urbieta, Ana
Heikkinen, Terho
Meijer, Adam
Fischer, Thea Kølsen
van den Berge, Maarten
Giaquinto, Carlo
Abram, Michael
Dormitzer, Philip
Stoszek, Sonia
Gallichan, Scott
Rosen, Brian
Molero, Eva
Machin, Nuria
Spadetto, Martina
Golubchik, Tanya https://orcid.org/0000-0003-2765-9828
Pollard, Andrew J. https://orcid.org/0000-0001-7361-719X
-
Funding
Funding for this research was provided by:
Innovative Medicines Initiative (116019)
EC | Horizon 2020 Framework Programme
European Federation of Pharmaceutical Industries and Associations
NIHR Oxford Biomedical Research Centre NIHR Thames Valley and South Midlands Clinical Research Network British Research Council REspiratory Syncytial virus Consortium in EUrope
- License Information
-
More Information
Article History
Received: 17 February 2021
Accepted: 21 July 2021
First Online: 26 August 2021
Change Date: 7 October 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41467-021-26291-y
Competing interests
: S.B.D. has been an investigator for clinical trials of vaccines and antimicrobials for pharmaceutical companies including AstraZeneca, Merck and Janssen, and sits on an RSV advisory board for Sanofi Pastuer. M.A.A. is supported by a Sir Henry Dale Fellowship jointly funded by the Royal Society and Wellcome Trust (220171/Z/20/Z). D.Ö. and J.A. are employees of Janssen Pharmaceutica NV. F.M.-T. has received honoraria from GSK, Pfizer Inc., Sanofi Pasteur, MSD, Seqirus and Janssen for taking part in advisory boards and expert meetings and for acting as a speaker in congresses outside the scope of the submitted work. F.M.-T. has also acted as principal investigator in randomised controlled trials of the above-mentioned companies as well as Ablynx, Regeneron, Roche, Abbott, Novavax and MedImmune, with honoraria paid to his institution. F.M.-T. receives support for his research activities from the Instituto de Salud Carlos III (Proyecto de Investigación en Salud, Acción Estratégica en Salud): Fondo de Investigación Sanitaria (FIS;PI1601569/PI1901090) del plan nacional de I+D+I and ‘fondos FEDER’. A.J.P. is a National Institute for Health Research (NIHR) Senior Investigator with funding from the British Research Council. The remaining authors declare no competing interests. The views expressed in this article are those of the authors and may not be understood or quoted as being made on behalf of or reflecting the position of the organisations with which the authors are employed/affiliated.
